| 1 |
Nasonov EL. Janus kinase inhibitors in immunoinflammatory rheumatic diseases. Terapevticheskii arkhiv 2022;94:605-609. [DOI: 10.26442/00403660.2022.05.201501] [Reference Citation Analysis]
|
| 2 |
Nasonov EL, Korotaeva TV. Janus kinase inhibitors in immunoinflammatory diseases: 10 years of clinical practice in rheumatology. Naučno-praktičeskaâ revmatologiâ 2022;60:131-148. [DOI: 10.47360/1995-4484-2022-131-148] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 3 |
Kovaleva YS, Orobei MV, Zyablitskaya NK. Selective reversible JAK1 inhibitor in the treatment of moderate and severe atopic dermatitis. Medicinskij sovet 2022. [DOI: 10.21518/2079-701x-2022-16-3-103-110] [Reference Citation Analysis]
|
| 4 |
Nasonov EL, Lila AM, Dubinina TV, Nikininskaya OA, Amirdjanova VN. Advances in rheumatology at the beginning of the 21st century. Naučno-praktičeskaâ revmatologiâ 2022;60:5-20. [DOI: 10.47360/1995-4484-2022-5-20] [Reference Citation Analysis]
|
| 5 |
Amirjanova VN, Karateev AE, Pogozheva EY, Baranov AA, Mazurov VI, Samigullina RR, Anoshenkova ON, Lapkina NA, Grineva TY, Nasonov EL, Lila AM. The first experience of using upadacitinib in the treatment of rheumatoid arthritis in real clinical practice (results of the multicenter project “RACURS”). Naučno-praktičeskaâ revmatologiâ 2021;59:571-577. [DOI: 10.47360/1995-4484-2021-571-577] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 6 |
Nasonov EL, Lila AM, Mazurov VI, Belov BS, Karateev AE, Dubinina TV, Nikitinskaya OA, Baranov AA, Abdulganieva DI, Moiseev SV, Zagrebneva AI. Coronavirus Disease 2019 (COVID-19) and Immune-mediated Rheumatic Diseases. Recommendations of the Association of Rheumatologists of Russia. Naučno-praktičeskaâ revmatologiâ 2021;59:239-254. [DOI: 10.47360/1995-4484-2021-239-254] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 10.5] [Reference Citation Analysis]
|
| 7 |
Nasonov EL. 2019 Coronavirus disease (COVID-19): contribution of rheumatology. Terapevticheskii arkhiv 2021;93. [DOI: 10.26442/00403660.2021.05.200799] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 8 |
Nasonov EL. Coronavirus disease 2019 (COVID-19) and autoimmunity. Naučno-praktičeskaâ revmatologiâ 2021;59:5-30. [DOI: 10.47360/1995-4484-2021-5-30] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 9 |
Nasonov EL, Lila AM. The progress of rheumatology in the 21st century potential uses of upadacitinib in rheumatoid arthritis and other inflammatory rheumatic diseases. Naučno-praktičeskaâ revmatologiâ 2020;58:532-543. [DOI: 10.47360/1995-4484-2020-532-543] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 10 |
Karateev AE. Problems of pain and quality of life in rheumatoid arthritis: focus on baricitinib. Naučno-praktičeskaâ revmatologiâ 2020;58:420-427. [DOI: 10.47360/1995-4484-2020-420-427] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
